Eylea package

Notice: Product images are for illustration purposes only and may differ from the medication you receive. Packaging and appearance may vary depending on the country of origin, and generic medications may be supplied by different manufacturers. The medication, strength, and active ingredients will match your prescription. At the Canadian Pharmacy Store we prioritize your health and safety by working with licensed pharmacy partners to provide safe, high-quality medications.

Eylea (Aflibercept)

Eylea

Aflibercept

Sourced from Canada Source: Canada
Prescription Required
Select product strength & quantity:
Select Strength & Quantity

Choose the strength, form, and package size that match your prescription.

Send Your Prescription

Upload your prescription online, request a transfer, or have your doctor fax us.

Pharmacist Review & Delivery

Reviewed by a licensed pharmacist and shipped to your U.S. address with tracking. Shipping details.

Description

Eylea (aflibercept) is a vascular endothelial growth factor inhibitor listed in our Eye care medications directory and prescribed for specified retinal or macular conditions (1.1) (2.1). Administered via the intravitreal route, Eylea is available for delivery to U.S. residents through Canadian Pharmacy Store with a valid prescription. Review the clinical fact table, dosage directions, cautions, drug interactions, side effects, and official regulatory sources below.

Eylea is a medication containing the active pharmaceutical ingredient aflibercept, classified pharmacologically as a vascular endothelial growth factor inhibitor (2.1). It is clinically indicated for the management of specified retinal or macular conditions as part of a comprehensive treatment plan supervised by a licensed healthcare provider (2.1).

Within the Eye care medications section of our catalogue, patients and prescribers frequently review Eylea alongside related therapies such as Lucentis (Ranibizumab), Vabysmo (Faricimab), Restasis (Cyclosporine), and Acetazolamide.

Official Indications and Usage

Eylea is indicated for the treatment of: Eylea is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) Macular Edema Following Retinal Vein Occlusion (RVO) Diabetic Macular Edema (DME) Diabetic Retinopathy (DR) Retinopathy of Prematurity (rop). (1.1)

Mechanism of Action and Pharmacology

Vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) are members of the VEGF family of angiogenic factors that can act as mitogenic, chemotactic, and vascular permeability factors for endothelial cells. VEGF acts via two receptor tyrosine kinases, VEGFR-1 and VEGFR-2, present on the surface of endothelial cells. PlGF binds only to VEGFR-1, which is also present on the surface of leucocytes. Activation of these receptors by VEGF-A can result in neovascularization and vascular permeability. Aflibercept acts as a soluble decoy receptor that binds VEGF-A and PlGF, and thereby can inhibit the binding and activation of these cognate VEGF receptors. (1.1)

What are Macular and retinal conditions?

Macular and retinal disorders affect light-sensitive tissue at the back of the eye. Similar symptoms can reflect different diseases and treatment needs. Explore related medications below and discuss treatment options with your healthcare provider. Read our complete Macular and retinal conditions condition guide for appointment questions and related therapies (2.1).

Ordering Eylea from Canada for U.S. Delivery

U.S. patients can order Eylea (Aflibercept) in U.S. dollars with a valid prescription from a U.S.-licensed clinician. Your card is only charged after your prescription passes pharmacist safety checks and is ready to ship.

Step 1

Send Your Prescription

Step 2

Pharmacist Safety Check

  • Multi-point dosing and interaction review completed in under 1 business day.
  • Mandatory licensed pharmacist consultation via phone, voicemail, or text before dispatch.
  • Verified under our Pharmacy Safety Standards.
Step 3

$14.99 USD Tracked Parcel

  • Packed in discreet protective packaging for a flat $14.99 USD per order ($29.99 if combined with cold-chain).
  • Tracked via Canada Post and USPS: 3 to 7 business days from Canada (7 to 14 days from international partners).
  • Review full shipping and delivery details.
Step 4

U.S. Street Delivery & Payment

  • Delivered to any physical U.S. street address with signature upon delivery (no P.O. Boxes).
  • You see and approve the country of origin upfront before your card is charged.
  • Report any delayed or damaged parcel within 48 hours for prompt resolution.

Fact Table

Clinical Specification Details
Brand / Product Name Eylea
Chemical / Generic Name Aflibercept
Pharmacological Class Vascular Endothelial Growth Factor Inhibitor
Therapeutic Category Eye care medications
Molecular Weight 97 g/mol (2.1)
Elimination Half-Life ~5 to 6 days (1.1)
Legal Status Rx-Only (Prescription Required)
Regulatory Reference Authorities U.S. FDA (DailyMed), Health Canada (DPD), NLM MedlinePlus
Routes of Administration Intravitreal
Dosage Forms & Strengths Eylea is a clear, colorless to pale yellow solution available as: Injection: 2 mg (0.05 mL of a 40 mg/mL solution) in a single-dose pre-filled glass
Primary Indications Specified Retinal Or Macular Conditions
Pregnancy & Breastfeeding Consult Doctor / Prescriber before use
FDA UNII Identifier 15C2VL427D
NLM RxNorm Concept ID (RxCUI) 1232154, 1232159, 2693564, 2693567
FDA Application License BLA125387
Official DailyMed SetID f96cfd69-da34-41ee-90a9-610a4655cd1c
Catalogue Index Links Letter E Index · All Medications · All Categories

Directions

Dosage and Administration Overview

Neovascular (Wet) Age-Related Macular Degeneration (AMD) The recommended dose for Eylea is 2 mg (0.05 mL of 40 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 days, monthly) for the first 3 months, followed by 2 mg (0.05 mL of 40 mg/mL solution) via intravitreal injection once every 8 weeks (2 months). Although Eylea may be dosed as frequently as 2 mg every 4 weeks (approximately every 25 days, monthly), additional efficacy was not demonstrated in most patients when Eylea was dosed every 4 weeks compared to every 8 weeks. Some patients may need every 4 week (monthly) dosing after the first 12 weeks (3 months). Although not as effective as the recommended every 8 week dosing regimen, patients may also be treated with one dose every 12 weeks after one year of effective therapy. Patients should be assessed regularly. (1.1)

Presentations and Strengths

Eylea is a clear, colorless to pale yellow solution available as: Injection: 2 mg (0.05 mL of a 40 mg/mL solution) in a single-dose pre-filled glass syringe Injection: 2 mg (0.05 mL of a 40 mg/mL solution) in a single-dose glass vial Injection: 2 mg (0.05 mL of 40 mg/mL) solution in a single-dose pre-filled syringe Injection: 2 mg (0.05 mL of 40 mg/mL) solution in a single-dose vial. (1.1)

Administration Guidance

Apply to the affected eye(s) exactly as directed on your prescription label (1.1). Wash your hands before use, avoid touching the dropper tip to the eye or any surface to prevent contamination, and wait at least 5 minutes between different ophthalmic drops.

Missed Dose Guidance

If you miss a scheduled dose of Eylea, follow the missed-dose instructions in the official patient leaflet or ask your pharmacist. Do not double the next dose to make up for a missed dose (2.1).

Ingredients

Active Pharmaceutical Ingredient

The active ingredient in Eylea is aflibercept (2.1).

Excipients and Formulation Carriers

Film coatings, stabilizers, and inactive carriers vary by strength and manufacturer presentation. If you have a known allergy to lactose, dyes, sulfites, or specific preservatives, ask our pharmacist to check the exact excipient list for your selected package (2.1).

Cautions and important safety information

Contraindications

Ocular or periocular infection Active intraocular inflammation Hypersensitivity. (1.1)

Key Clinical Precautions

Before starting or continuing Eylea, discuss your complete medical history with your healthcare provider. Key clinical cautions include (1.1):

  • Cardiovascular events: Depending on the medication class and underlying medical history, patients should be monitored for signs of cardiovascular events such as chest pain, shortness of breath, sudden weakness, or slurred speech.

Pregnancy, Lactation, and Special Populations

Adequate and well-controlled studies with Eylea have not been conducted in pregnant women. Aflibercept produced adverse embryofetal effects in rabbits, including external, visceral, and skeletal malformations. A fetal No Observed Adverse Effect Level (noael) was not identified. At the lowest dose shown to produce adverse embryofetal effects, systemic exposures (based on AUC for free aflibercept) were approximately 6 times higher than AUC values observed in humans after a single intravitreal treatment at the recommended clinical dose. (1.1)

Interactions

Always provide your prescribing physician and pharmacist with an up-to-date list of all prescription medications, over-the-counter products, vitamins, and herbal supplements you take before starting Eylea (2.1).

Side effects

Like all medications, Eylea can cause side effects, although not everyone experiences them. Commonly reported side effects in clinical trials and official labeling include (1.1):

  • Peripheral edema (swelling of ankles, feet, or hands): Fluid retention may occur; notify your doctor if swelling is rapid or accompanied by shortness of breath.
  • Injection- or application-site reactions: Mild redness, itching, tenderness, or bruising at the administration site; rotating injection sites as directed helps minimize local irritation.

Clinical Trial and Postmarketing Adverse Reactions

The following potentially serious adverse reactions are described elsewhere in the labeling: Hypersensitivity Endophthalmitis, Retinal Detachments, and Retinal Vasculitis with or without Occlusion Increase in intraocular pressure Thromboembolic events The most common adverse reactions (≥5%) reported in patients receiving Eylea were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in other clinical trials of the same or another drug and may not reflect the rates observed in practice. (1.1)

When to Seek Immediate Medical Attention

Contact your physician or seek urgent medical care if you experience signs of a severe allergic reaction (hives, difficulty breathing, or swelling of the face, lips, tongue, or throat), severe dizziness or fainting, unexplained severe pain, or any sudden change in your clinical symptoms (2.1).

Storage and handling

Handling Refrigerate Eylea at 2°C to 8°C (36°F to 46°F). Do not freeze. Do not use beyond the date stamped on the carton and container label. Store in the original carton until time of use to protect from light. Do not open sealed blister tray until time of use. (1.1)

Store Eylea in its original container at controlled room temperature away from excess heat, direct light, and moisture (such as bathroom cabinets), and keep out of reach of children and pets (1.1).

Frequently Asked Questions About Eylea

What is Eylea and what active ingredient does it contain?

Eylea is a vascular endothelial growth factor inhibitor containing the active pharmaceutical ingredient aflibercept. It is supplied for intravitreal administration and requires a valid prescription where applicable.

How does Eylea work in the body?

Vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) are members of the VEGF family of angiogenic factors that can act as mitogenic, chemotactic, and vascular permeability factors for endothelial cells. VEGF acts via two receptor tyrosine kinases, VEGFR-1 and VEGFR-2, present on the surface of endothelial cells. PlGF binds only to VEGFR-1, which is also present on the surface of leucocytes.

What conditions is Eylea prescribed to treat?

Eylea is primarily indicated for specified retinal or macular conditions. Your prescribing clinician determines the appropriate indication, strength, and treatment duration based on your individual diagnosis and medical history.

How should I take or use Eylea?

Follow the exact dosage, frequency, and administration instructions printed on your prescription label. Eylea is administered via the intravitreal route. Administer it consistently at the same time(s) as directed, and never adjust your dose or stop therapy without speaking with your prescriber.

What are the most common side effects of Eylea?

Commonly reported side effects of Eylea include swelling and a reaction at the treatment site. Most mild side effects improve as your body adjusts to treatment, but you should notify your doctor or pharmacist if symptoms persist or worsen.

What medications or substances can interact with Eylea?

Share your full list of current prescription medications, over-the-counter products, and supplements with your prescriber and pharmacist so they can screen for any potential drug interactions.

Can Eylea be used during pregnancy or breastfeeding?

If you are pregnant, planning to become pregnant, or breastfeeding, consult your prescribing physician before using Eylea to weigh the clinical benefits and potential risks.

Do I need a prescription to buy Eylea online from Canada?

Yes. A valid prescription written by a U.S.-licensed physician, nurse practitioner, or physician assistant is required to buy Eylea (Aflibercept) through our licensed Canadian pharmacy partners. Valid prescriptions go through multiple safety checks in less than 1 business day, followed by a mandatory request to speak with a licensed pharmacist for a consultation (watch your phone, voicemails, and text messages).

Does Eylea have a generic equivalent (Aflibercept) at a Canada pharmacy?

Currently, Eylea (Aflibercept) is dispensed in our catalogue as a brand-name formulation. Check our Aflibercept active ingredient hub for updates as licensed generic presentations become available.

How is Eylea shipped to U.S. residents, and how much does shipping cost?

Eylea ships in discreet protective packaging at a flat rate of $14.99 USD per order via Canada Post and USPS with full tracking (if combined in the same order with a cold-chain item, total shipping is $29.99 USD in a larger container). Once your valid prescription passes safety checks (<1 business day) and you respond to the mandatory licensed pharmacist consultation request via phone, voicemail, or text message, delivery takes 3 to 7 business days from Manitoba, Canada (or 7 to 14 business days from licensed partner pharmacies in the UK, Singapore, and Mauritius). You see and choose the country of origin before you pay, and your Visa, Mastercard, or Discover card is only charged when your order is ready to ship.

How can I send or transfer my Eylea prescription, or ask about an unlisted strength?

You can upload a clear photo or PDF of your Eylea prescription online, request a prescription transfer or direct prescriber coordination from our team, or have your prescriber fax the prescription directly to (844) 666 – 6819. You may order up to a 90-day personal-use supply per shipment. If you do not see your exact prescribed strength or manufacturer listed, call 1-888-868-1920 and our staff will check availability across our licensed pharmacy partners.

References & Official Sources

Clinical, pharmacological, and safety facts for Eylea (Aflibercept) are compiled directly from official regulatory prescribing labels and primary biomedical databases:

  1. (1.1) Eylea (Aflibercept), Official Prescribing Information. U.S. National Library of Medicine / U.S. Food and Drug Administration (DailyMed). Official U.S. FDA / DailyMed Structured Product Labeling (SPL). (Accessed 2026-10-29).
  2. (2.1) MedlinePlus Medical Encyclopedia: Macular Degeneration. MedlinePlus / National Library of Medicine. U.S. National Library of Medicine, MedlinePlus Drug & Health Information. (Accessed 2026-10-29).
  3. (3.1) Health Canada Drug Product Database (DPD), Authorized Product Records. Health Canada / Government of Canada. Health Canada Drug Product Database & Official Product Monograph. (Accessed 2026-10-29).

Related Condition Guides

Related Guides

Call 1-888-868-1920Help